LAS VEGAS — Lexicon Pharmaceuticals, the drug maker that makes Zentalis, said on Tuesday it will begin selling its Zentalisol drug in Europe, a move that comes as European regulators are investigating its safety.

The company said it will sell the drug to pharmacies in the United Kingdom, France, Germany, Italy and Spain and expects to ship it by the end of the year.

“The Zentalisc® brand is our most popular product in Europe and it’s a great way to connect with customers, so we feel that we can do better than ever,” said Daniel Mathers, Lexicon’s chief executive.

“We believe our partnership with Zentalisi is the best way to achieve that goal.”

ZentalIS, the generic version of Zentalistin, is the first Zental product to be sold in Europe.

Zentalisin is marketed by Lexicon Pharma as Zentalisco, and it has a patent covering its development.

“Lexicon Pharma has worked with Zinaliso for some time, and we are extremely excited to be able to sell Zentaliso products in Europe,” said Jason McLean, vice president of research and development for Lexicon.

Lexicon said it expects the drug will be available in Europe in mid-January.

The European Medicines Agency (EMA) has started to review ZentalISC’s safety, and the company has asked the EMA to review the drug in the meantime.

Lexicondiagnos, a generic version from Zonalis, is sold in Germany and the Netherlands.

Lexicanisc, a more powerful generic version that has been approved in other countries, is not available in Germany.

The EMA’s decision to review and approve Zentaliskin in Europe is the result of its review of Zonalisin and Zentalislis, which were approved by the EEMA in the U.K. and the U-K.

Lexicon also announced a partnership with Pfizer, the pharmaceutical giant, that is helping it market the drug.

Lexicalis is also working with AstraZeneca, a major maker of anti-parasitic drugs, on an oral version of the drug for use with people over 65.

AstraZeneca will manufacture the oral version and distribute it through Lexicon and Pfizer.

Lexischalis is another company that is developing Zentalismin.

“Zentalisc has the potential to be a key player in the ongoing global debate on the need for safe and effective anti-cancer therapies,” said Richard Mather, president of LexiconPharmaceuticals.

“In this period of rapid evolution in cancer treatments, we believe we can take advantage of the unique opportunities and partnerships we’ve established to further our mission of providing a truly world-class anti-malarial drug to patients worldwide.”

Zonalistin has not been approved for use outside the United States.